Core Viewpoint - Zoetis Inc. is a leading animal health company facing challenges in stock performance and revenue growth due to various market and company-specific factors [2][5]. Company Overview - Zoetis Inc. has a market capitalization of $56.3 billion and specializes in animal health products, including medicines, vaccines, and diagnostic solutions for both livestock and companion animals [1]. Stock Performance - Over the past 52 weeks, Zoetis shares have decreased by 27.5%, underperforming the S&P 500 Index, which gained 12.2% during the same period [2]. - Year-to-date, Zoetis shares have gained 1.3%, contrasting with a slight decline in the S&P 500 Index [2]. Competitive Analysis - Zoetis has also lagged behind the State Street Health Care Select Sector SPDR ETF, which has seen a 5.4% increase over the past year [3]. Financial Performance - In Q3 2025, Zoetis reported revenue of approximately $2.4 billion, reflecting a modest year-over-year increase of about 1% [6]. - Analysts project a 7.1% year-over-year growth in EPS for the fiscal year 2025, estimating it to reach $6.34 [6]. Analyst Ratings - The consensus rating among 17 analysts covering Zoetis is a "Moderate Buy," with eight "Strong Buy" ratings, one "Moderate Buy," and eight "Holds" [6]. - This rating configuration has become less bullish compared to three months ago, when there were 11 "Strong Buy" ratings [7]. Recent Downgrade - On January 22, 2026, Piper Sandler analyst David Westenberg downgraded Zoetis from "Overweight" to "Neutral" and reduced the price target from $190 to $135 [7].

Company Overview - Zoetis (ZTS) is expected to report flat earnings of $1.40 per share for the quarter ended December 2025, with revenues projected at $2.37 billion, reflecting a 2.1% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - A positive Earnings ESP of +0.84% suggests that analysts are optimistic about Zoetis's earnings prospects, although the company holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Zoetis exceeded the expected earnings of $1.62 per share by delivering $1.70, resulting in a surprise of +4.94% [13]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [14]. Industry Context - In comparison, Neurocrine Biosciences (NBIX) is expected to post earnings of $2.25 per share for the same quarter, marking a significant year-over-year increase of +125%, with revenues anticipated to rise by 25% to $784.42 million [18].

Group 1 - Zoetis (ZTS) stock decreased by 2.02% to $122.41, underperforming the S&P 500, which fell by 0.84% [1] - Prior to the recent trading session, Zoetis shares had declined by 3.42%, lagging behind the Medical sector's gain of 0.16% and the S&P 500's gain of 1.8% [1] Group 2 - The upcoming earnings report for Zoetis is scheduled for February 12, 2026, with projected earnings per share (EPS) of $1.4, indicating no change from the same quarter last year [2] - Revenue is estimated to be $2.37 billion, reflecting a 2.08% increase compared to the same quarter of the previous year [2] Group 3 - For the full year, analysts expect earnings of $6.34 per share and revenue of $9.45 billion, representing changes of +7.09% and 0%, respectively, from last year [3] Group 4 - Recent adjustments to analyst estimates for Zoetis are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] Group 5 - Changes in estimates are directly related to stock price performance, and the Zacks Rank system incorporates these changes to provide a rating system [5] Group 6 - Zoetis currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 18.36, which is a premium compared to the industry average Forward P/E of 17.2 [6] Group 7 - The company has a PEG ratio of 2.16, while the Medical - Drugs industry has an average PEG ratio of 1.15 [7] - The Medical - Drugs industry is ranked 159 in the Zacks Industry Rank, placing it in the bottom 36% of over 250 industries [7] Group 8 - The Zacks Industry Rank evaluates the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [8]

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a pr ...

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

Core Viewpoint - Diamond Hill Capital's "Large Cap Fund" investor letter for Q4 2025 highlights a cautious stance on AI-driven market enthusiasm while emphasizing the attractiveness of fundamentally stable, high-quality, cash-generative businesses [1] Group 1: Market Performance - The Russell 1000 Value Index increased by 3.8% in Q4 2025, with the information technology sector rising by 11% and communication services by 9%, driven by AI optimism [1] - The Fund returned 1.41% in Q4, underperforming the Russell 1000 Value Index [1] Group 2: Zoetis Inc. Performance - Zoetis Inc. (NYSE:ZTS) is identified as a leading relative detractor for the Fund, with its stock closing at $124.94 on February 2, 2026, and a 27.46% decline over the past twelve months [2][3] - The company reduced its 2026 outlook due to fewer veterinary visits by pet owners, leading to underperformance in Q4 [3] Group 3: Investment Sentiment - Despite acknowledging Zoetis Inc.'s potential, the company is not among the 30 most popular stocks among hedge funds, with a decrease in hedge fund portfolios holding the stock from 75 to 72 [4] - The Fund believes certain AI stocks present greater upside potential and less downside risk compared to Zoetis Inc. [4]

Market Performance - The broad U.S. market started the year positively, with the SPDR® S&P 500® ETF (SPY) posting a gain despite some elevated volatility in the final week of January [1]

Group 1 - Zoetis Inc. (NYSE:ZTS) is recognized as one of the most profitable healthcare stocks to consider for investment, with a current price target of $130 set by Stifel Nicolaus, indicating a potential upside of 4.91% [1] - Piper Sandler downgraded Zoetis from Overweight to Neutral, reducing the price target from $190 to $135, citing concerns over the company's innovation timeline and projecting a potential "innovation air pocket" lasting one to two years [2] - Morgan Stanley also adjusted its price target for Zoetis, lowering it from $175 to $160 while maintaining an Overweight rating, suggesting a favorable environment for healthcare companies in 2026 despite current challenges in managed care stocks [3] Group 2 - Zoetis Inc. is a New Jersey-based company established in 1950, specializing in a range of health products including animal health medicines, vaccines, biodevices, and genetic tests, with a goal to become the most valuable animal health company [4]

Group 1 - The soft commodity sector, including grains, livestock, and dairy products, is gaining momentum and attracting market attention, alongside the strong performance of hard commodities like gold and silver [1] - The VanEck Agribusiness ETF (MOO.US) offers diversified exposure across the agricultural value chain, including fertilizers, machinery, and food processing, rather than solely betting on spot prices [1] - Nutrien (NTR.US) has seen a nearly 20% increase over the past two weeks and is considered a strong stock in the agricultural sector [1] Group 2 - CF Industries Holdings (CF.US) has risen over 18% year-to-date and has recorded four consecutive weeks of gains, marking its longest winning streak since last year [2] - Archer Daniels Midland (ADM.US) has increased approximately 17% this year, with a dividend yield close to 3%, and has recently broken through the key $65 resistance level [2] - Darling Ingredients (DAR.US) has seen a cumulative increase of about 23% over the past three months, with its stock price recently surpassing the critical $40 resistance level [2]

Core Viewpoint - Zoetis Inc. is experiencing near-term uncertainty but maintains long-term appeal due to its diverse product pipeline and potential blockbuster candidates [2][3][4]. Group 1: Analyst Downgrade and Market Sentiment - Piper Sandler downgraded Zoetis from Overweight to Neutral and reduced its price target from $190 to $135, citing uncertainty in the near term [2]. - The firm expressed concerns about the current consumer spending environment and its impact on Zoetis' planned product launches in 2026 [3]. Group 2: Product Pipeline and Innovation - Zoetis is described as being in an "innovation lull," with a potential air pocket lasting one to two years, which raises questions about its near-term growth [3]. - The company highlighted a robust pipeline during its Innovation Webcast, featuring 12 candidates with blockbuster potential across various therapeutic areas, including chronic kidney disease and oncology [4]. - Zoetis is also focusing on next-generation treatments in established franchises such as osteoarthritis pain and dermatology, indicating a balanced strategy of geographic expansion and lifecycle extensions [5]. Group 3: Company Overview - Zoetis Inc. is a global leader in animal health, dedicated to developing and commercializing a wide range of products, including medicines, vaccines, diagnostics, and precision health tools for animals [6].